title: [Anemia management in French hemodialysis patients: DiaNE study results at 3 years (DiaNE2)].
abstract: The observational study DiaNE provides a current state of anemia management with Epoetine bêta in hemodialysis patients regarding European recommendations over a 3-year period in France. Patients still treated with Epoetine bêta twelve months after their inclusion in DiaNE were eligible for a 24-month extension phase entitled DiaNE 2. Data regarding 439 patients followed during three years, from M0 to M36, were analyzed. Hemoglobin (Hb) level of the cohort remained over the target value of 11g/dL during the study (M0: 11.3±1.2g/dL; M36: 11.8±1.3g/dL). The anemia management had evolved with European recommendations updates and was in accordance with the last recommended target range (11-12g/dL) in a third of patients. During the follow-up, the majority of patients (97%) had at least one modification of treatment with Epoetine bêta (change in frequency of injections, adjustment of doses) mainly justified by excursion of Hb level out of the target range. However, the median dose of Epoetine bêta was relatively stable. The number of patients with iron treatment remained stable (60%). In spite of undertaken efforts, anemia management of hemodialysed patients in France still needs optimization for maintaining Hb level in the recommended target range.
authors.affiliation: Hôpitaux de Brabus, Vandœuvre-lès-Nancy, France. m.kessler@chu-nancy.fr
authors.forename: Michèle
authors.initials: M
authors.lastname: Kessler
authors.forename: Paul
authors.initials: P
authors.lastname: Landais
authors.forename: Pierre
authors.initials: P
authors.lastname: Bataille
authors.forename: Laurent
authors.initials: L
authors.lastname: Yver
authors.forename: Sébastien
authors.initials: S
authors.lastname: Koné
authors.forename: Sandrine
authors.initials: S
authors.lastname: Kraemer
authors.forename: Georges
authors.initials: G
authors.lastname: Brillet
authors.forename: Eric
authors.initials: E
authors.lastname: Canivet
mesh_terms: D000368:Aged; D000740:Anemia / Q000188:drug therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D011994:Recombinant Proteins; D006435:Renal Dialysis; D013997:Time Factors
chemical_list: D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin